Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes

While the bone marrow in most patients with myelodysplastic syndromes (MDS) has normal or increased cellularity (hyper-MDS), approximately 10%–15% of MDS patients will present with a hypocellular bone marrow (hypo-MDS).[1][1] Since the diagnosis of MDS relies mainly on the presence of dyplastic

[1]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[2]  G. Mufti,et al.  Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome. , 2014, Blood.

[3]  C Haferlach,et al.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.

[4]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[5]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[6]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[7]  R. Calado.  Immunologic aspects of hypoplastic myelodysplastic syndrome. , 2011, Seminars in oncology.

[8]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[9]  C. O'keefe,et al.  SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. , 2011, Blood.

[10]  A. Barrett,et al.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. , 2010, Hematology/oncology clinics of North America.

[11]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[12]  E. Sloand.  Hypocellular myelodysplasia. , 2009, Hematology/oncology clinics of North America.

[13]  M. Yao,et al.  Comparison of hypoplastic myelodysplastic syndrome (MDS) with normo-/hypercellular MDS by International Prognostic Scoring System, cytogenetic and genetic studies , 2008, Leukemia.

[14]  E. Estey,et al.  Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes , 2003, Leukemia.